Introduction
Genome-wide association studies (GWAS) have yielded an extraordinary and unprecedented trove of new knowledge about the genetic causes of human disease. Since 2005, well over 600 human GWAS have been published, yielding genetic associations meeting stringent statistical significance (Pe'er et al., 2008) relevant to the etiology of 92 diseases and 117 other traits (Hindorff et al., 2009 ). Many of these GWAS findings have been surprising and have engendered new ideas about disease etiology. Because exposure to genetic variation begins at the earliest stage of development, we can generally be confident that genetic risk factors are at the beginning of the causal chain that leads to disease perhaps decades later. Thus, each association is a starting point, a hard clue about disease etiology. As an example from outside of neuroscience, in Crohn's disease, GWAS implicated genes involved in macroautophagy which has provided important insights into pathogenesis (Klionsky, 2009) . The notably strong association of complement factor H (CFH) with age-related macular degeneration has engendered renewed interest in the role of CFH in initiating the disease process rather than as epiphenomenon associated with the disease. In schizophrenia, multiple independent studies have implicated the major histocompatibility region (International Schizophrenia Consortium et al., 2009; Shi et al., 2009; Stefansson et al., 2009 ) raising the intriguing possibility of an etiological role for an immune, autoimmune, or infectious process. In addition, some studies have highlighted the role of alternative ways in which genetic variation might be etiological, including the importance of copy number variation (Sebat et al., 2009 ) and even compelling empirical data that schizophrenia results from the cumulative effects of thousands of different genetic variants in an as yet unknown biological pathway (International Schizophrenia Consortium et al., 2009) .
Even the most cursory review of the GWAS literature reveals that the critical ingredient to success is large samples for initial discovery and replication. Sample size requirements can easily exceed 10,000 cases and 10,000 controls. Obtaining such historically massive sample sizes is beyond the reach of any single group. Therefore, close cooperation among groups has become essential to progress in human genetics.
The purpose of this Neuron NeuroView is to describe the Psychiatric GenomeWide Association Consortium (PGC) which was created in an attempt to conduct large-scale mega-analyses of GWAS data for psychiatric disorders. Psychiatric diseases are compelling targets for genetics research-they are mostly idiopathic, first-rank public health problems, and cause enormous morbidity, mortality, and personal/societal cost. Moreover, despite considerable research, little is known for certain about disease etiology. The fact that disease definition in psychiatry is descriptive poses particular problems. The diagnostic process relies heavily on signs and symptoms without recourse to biological means of distinguishing affected from unaffected individuals. This poses unique challenges for genetic studies. Although the PGC's focus has been in the area of psychiatric genetics, the organization and consortia approach which the PGC exemplifies could be a model for other disorders and more broadly, even outside of genetics, for other research communities applying high-throughput analytic approaches to biological problems.
GWAS Background
As the GWAS method has been reviewed extensively, only a brief description is given here and Table 1 provides ample opportunities for further reading. A GWAS for a human disease is usually a variant of a cross-sectional case-control study, the familiar workhorse in biomedicine. Cases meet lifetime criteria for a disease (e.g., schizophrenia) and controls should have never met criteria and, ideally, be through the period of risk. Each individual in the sample is genotyped for a predefined set of a million or more genetic markers spaced across the genome. The genetic markers are single nucleotide polymorphisms (SNPs, ''snips'') which are relatively straightforward to assay in a highly multiplexed fashion. After careful quality control, each SNP is tested for association with disease. In effect, these tests compare the allele frequencies in cases versus controls, and a large casecontrol difference suggests an etiological role for a particular SNP or its genomic region. Because of the large numbers of statistical comparisons, the laws of probability mandate correction for multiple comparisons. A typical type 1 error threshold for genome-wide significance is often taken to be 5 3 10 À8 (akin to a Bonferroni correction of 0.05 divided by 1 million tests) (Pe'er et al., 2008) .
Psychiatric GWAS Consortium (PGC): Background and Science As increasing numbers of GWAS were published in [2005] [2006] , it became apparent that typical sample sizes (e.g., 1000 cases and 1000 controls) did not usually lead to associations that exceeded chance levels of significance. Such findings provided, for the first time, evidence that the genetic effect sizes for common variation were considerably smaller than had been appreciated. For example, in the pre-GWAS era, many investigators powered their studies to detect genotypic relative risks of $1.54 (1000 cases/1000 controls, a = 5 3 10 À8 , and 90% power). Using the NHGRI GWAS catalog (Hindorff et al., 2009 ; Figure 1 ), the typical genotypic relative in a GWAS is far smaller than appreciated previously (median of 1.28) which necessitates a sample size of over 3000 cases and 3000 controls. To identify the 25 th percentile genotypic relative risk of 1.18 requires nearly 7000 cases and 7000 controls.
Thus, assumptions about power and sample size required revision; studies which seemed well-powered when they began were too small. It became obvious that larger sample sizes were needed and groups working together were the only practical way to achieve this end. Consortia were thus an immediate solution. The concept of working together was influenced by the experiences of other biomedical disorders. For example, the initial three GWAS for type 2 diabetes mellitus were only modestly successful but joint analysis revealed many more strongly significant associations.
The PGC began on a teleconference in March 2007 between principal investigators who had GWAS funded for attention deficit hyperactivity disorder (ADHD), bipolar disorder, major depressive disorder, and schizophrenia as part of a Foundation for the NIH initiative (Manolio et al., 2007) . Even though, at the time, this project was at early stages and as no psychiatric GWAS had yet been published, we were already concerned about power and hence initiated plans for joint analysis of our results. This effort rapidly expanded to include autism, the other major psychiatric disorder with a considerable body of GWAS data. Subsequently, all investigators in the field with data for these five disorders were invited to join the PGC. All but one group invited has joined.
The overarching purpose of the PGC is to conduct high-quality GWAS megaanalyses in order to foster rapid progress in what has been a complex and uncertain scientific area. These results are meant to inform research into ADHD, autism, bipolar disorder, major depressive disorder, and schizophrenia along with searches for genetic loci that predispose to more than one disorder. The initial iteration of the PGC had four scientific aims, which were designed to facilitate the overarching scientific goal of attempting to identify secure associations of comprehensive assessment of common genetic variation with five critically important psychiatric diseases.
The first aim involved dataset harmonization. Experience has taught us that unless this is conducted with expertise and great care, inference is not secure. Harmonization and quality control apply to each step of the GWAS processascertainment of subjects, diagnostic procedures, genotyping, removal of subjects, and SNPs with unconfident data and with extensive searches for bias. For the PGC, raw individual-level and deidentified phenotype and genotype data from each study were uploaded to a highperformance computing cluster and processed through a robust and comprehensive quality control pipeline conforming to best-practice protocols in order to minimize chances of false positive results (e.g., due to population stratification). As the individual studies used different genotyping platforms, the cleaned data were imputed against a widely used panel of data from European subjects (HapMap3) so that all studies had a common set of genotypes. In addition, considerable efforts were made to harmonize phenotype data by ensuring that all studies used comparable diagnostic constructs and to database item-level data.
The second aim entailed withindisorder meta-analyses-five different mega-analyses of all available GWAS data for ADHD, autism, bipolar disorder, major depressive disorder, and schizophrenia, to attempt to identify convincing genotype-phenotype associations.
The point of the third aim is specific to psychiatry. Throughout the history of psychiatry, diagnoses have been made based on signs and symptoms accrued (Kendell and Brockington, 1980; Kendell, 1989) , This aim attempts to identify convincing genetic associations that are common to two or more of ADHD, autism, bipolar disorder, major depressive disorder, and schizophrenia. This work could provide critical insight into how these disorders are similar and different.
The fourth aim is related to data sharing. Consistent with the goal of rapid progress, we have been communicating prepublication results widely. Where informed consent and Ethical Committee rulings allow, deidentified phenotype, genotype, and mega-analysis results will be deposited into controlled-access repositories (e.g., dbGaP, NCBI Database of Genotypes and Phenotypes) (Mailman et al., 2007) in order to make these data available for future use by the international scientific community.
Since the formation of the PGC, as we move forward, we plan for a new set of aims to continue the work of the PGC. The new aims include a comprehensive assessment of copy number variation and extension of the analytic pipeline to encompass next-generation sequencing data.
The Practical Side of the PGC By virtue of the numbers of investigators, subjects, and data points, the PGC is the largest consortium and biological experiment in the history of psychiatry. The PGC currently has over 160 investigators from 65 institutions in 19 countries. Membership has been extended to groups with high-quality GWAS data and usually includes the study principal investigator and key collaborators. Joining the PGC entails reading and agreeing to the rules of behavior detailed in a memorandum of understanding. Assent is indicated by email and effectively constitutes a pledge to behave with integrity. The PGC sponsored a series of papers outlining the history of genetic inquiries in psychiatry, a framework for interpretation of GWAS, and issues pertaining to comorbidity between disorders (Table 1) .
Participation in the PGC is driven by varying combinations of altruism and enlightened self-interest. Some investigators are inherently collegial and enjoy consortia whereas others would prefer to work independently but have come to believe cooperation is essential for progress. Others are motivated by different imperatives and we are aware that some in the field have chosen not to join given difficulties in functioning comfortably and effectively in a group context.
The PGC consists of a coordinating committee, five disease working groups (ADHD, autism, bipolar, major depressive disorder, and schizophrenia), the crossdisorder working group, and a statistical analysis group that has a CNV subgroup. Working group chairs are as follows: ADHD, Dr. Stephen Faraone; autism, Drs. Bernie Devlin and Mark Daly; bipolar disorder, Drs. John Kelsoe and Pamela Sklar; major depressive disorder, Dr. Patrick Sullivan; schizophrenia, Dr. Pablo Gejman; statistical analysis, Dr. Mark Daly; cross-disorder, Drs. Nick Craddock, Jordan Smoller, and Ken Kendler; and CNV, Drs. Mark Daly, Steven Scherer, and Jonathan Sebat. Dr. Sullivan also chairs the coordinating committee. Additional GWAS for anorexia nervosa and obsessive-compulsive disorder are becoming available and will become part of the PGC in the near future. There are notable computational demands for a project of this scale. We are deeply indebted to Dr. Danielle Posthuma (Vrije University Amsterdam) for facilitating the use of a cluster farm in the Netherlands for data warehousing and analysis. Depicted are 587 associations for 76 human diseases. Each association is plotted as its genotypic relative risk by the risk allele frequency in controls (both on log 10 scale). The insert shows the 10 diseases with the greatest numbers of associations. Red crosses show findings for neurological disorders (Alzheimer disease, amyotrophic lateral sclerosis, essential tremor, multiple sclerosis, narcolepsy, and Parkinson disease). Psychiatric disorders are indicated with plus marks including autism (blue), mood disorders (green), and schizophrenia (fuchsia). All other biomedical disorders are shown by gray dots.
The use of this cluster has provided a neutral platform for analyses.
From the beginning, the overall philosophy of the PGC has been to be as inclusive, democratic, transparent, and rapid as possible. No single individual or group dominates. The role of the coordinating committee is to adjudicate procedural issues of relevance to the whole consortium (e.g., to integrate efforts of the working groups and to secure the needed resources). A metaphor for the relationship between the coordinating committee and the working groups is the recurrent theme of United States history, the tension between federalism and ''states' rights.'' The belief is that the best science will emerge if the balance is decidedly shifted toward ''states' rights.'' The ''federal'' coordinating committee has a non-intrusive and facilitating role and all other decisions are delegated to the scientists who understand the issues best. There are often differences of opinion. These are almost always resolved by discussion. Rarely, discussion did not lead to resolution and necessitated a vote (simple majority, one vote per group contributing data).
A key principle has been that groups participate in the PGC at a time appropriate for their group. In practice, this was usually after their GWAS primary manuscript was accepted for publication. Participation in the PGC does not preclude any other academic effort (for courtesy, however, investigators inform their colleagues about any competing activities). An early decision adopted by all working groups was to publish under a consortium byline with all members of that working group listed as ''collaborators'' in PubMed (see http://www.ncbi. nlm.nih.gov/pubmed/17554300 for an example). This practical decision allowed the focus to remain on collaborative science and negated the otherwise inevitable jockeying for priority authorship positions. As a result of the clear and consistent application of these basic principles, the PGC has been running smoothly for several years despite its large membership. We note that no one who joined the PGC has quit.
The goal of the PGC is rapid and unfettered progress. As part of the Memorandum of Understanding, PGC members agreed that all genotype and phenotype data should be kept strictly confidential within that working group. Moreover, when the analyses for a specific aim were completed, the results could be freely discussed and participants were free to initiate follow-up experiments. In the interests of maximal progress, we encouraged prepublication sharing of follow-up experiments. However, the results could not be used in presentations or publications without prior approval.
The PGC encourages a responsible approach to management of intellectual property derived from downstream discoveries that is consistent with the recommendations of the NIH's Best Practices for the Licensing of Genomic Inventions and Research Tools Policy (http://www.ott.nih.gov/policy/genomic_ invention.html and http://ott.od.nih.gov/ policy/research_tool.html). In particular, management of patent applications in a manner that restricts use of any findings or that might diminish the value and public benefit provided by these resources is discouraged.
Finally, all PGS members were required to share the commitment to protect the confidentiality of data and to protect the joint analysis activity by insuring that no data were released or published in advance of an agreed-upon group publication and/or data release.
How Can Genetics Inform Neurobiology?
The fundamental goal of the PGC is to derive ''maps'' of the genetic architecture for the major psychiatric disorders, ADHD, autism, bipolar disorder, major depressive disorder, and schizophrenia. What does this mean for neuroscientists working on understanding the mechanisms of these disorders? Or to clinicians and patients looking for therapies or at least a better understanding of these disorders and their causes?
For scientists who study processes fundamental to the development of the central nervous system and its function in health and disease, these results are likely to be highly relevant. Genetic risk factors will include a spectrum of variation, from rare variants of strong effect to common variants of more subtle effect. Moreover, these data are likely to uncover novel similarities between currently distinctive disorders and new ways in which genetic changes can lead to disease (e.g., copy number variation and highly polygenic models).
It has now been widely observed that GWAS findings only infrequently implicate the ''usual suspects.'' In other words, when GWAS identifies a high-confidence and replicated finding, the loci implicated often point in a novel direction and these new leads can then become targeted priorities for more mechanistically oriented experimental work. While the holy grail of GWAS may be the identification of a strongly associated risk allele, as more associations emerge from GWAS and other genomic approaches and these findings are replicated, even apparently modest risk alleles may point us toward relevant biological pathways and networks.
Historically, there has been a gap between psychiatric genetics and neuroscience. In an idealized universe, psychiatric genetics and neuroscience would have rather symbiotic relations. In this way, we may well find that a genetic, molecular, or neuronal process being studied in a lab for one set of reasons ends up emerging as a potentially critical factor for a psychiatric disorder, based on genetic data. Ultimately, it's this kind of synergy, between genetics and biology, which will pave the path to true understanding of how genotype confers risk for phenotype and gives us the best chance of really understanding these disorders and paving the way for more effective therapies.
